Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 7
1994 5
1995 3
1996 6
1997 9
1998 19
1999 19
2000 23
2001 36
2002 32
2003 29
2004 32
2005 25
2006 33
2007 35
2008 36
2009 45
2010 43
2011 40
2012 52
2013 70
2014 97
2015 108
2016 99
2017 101
2018 112
2019 128
2020 172
2021 214
2022 188
2023 227
2024 290
2025 100

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,159 results

Results by year

Filters applied: . Clear all
Page 1
SMARCA4: Current status and future perspectives in non-small-cell lung cancer.
Tian Y, Xu L, Li X, Li H, Zhao M. Tian Y, et al. Cancer Lett. 2023 Feb 1;554:216022. doi: 10.1016/j.canlet.2022.216022. Epub 2022 Nov 28. Cancer Lett. 2023. PMID: 36450331 Free article. Review.
Furthermore, NSCLC patients with SMARCA4 alterations have a weak response to conventional chemotherapy and poor prognosis. ...This review systematically describes the biological functions of SMARCA4 and its role in NSCLC development, metastasis, functional epigeneti …
Furthermore, NSCLC patients with SMARCA4 alterations have a weak response to conventional chemotherapy and poor prognosis. ...This re …
SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy.
Mardinian K, Adashek JJ, Botta GP, Kato S, Kurzrock R. Mardinian K, et al. Mol Cancer Ther. 2021 Dec;20(12):2341-2351. doi: 10.1158/1535-7163.MCT-21-0433. Epub 2021 Oct 12. Mol Cancer Ther. 2021. PMID: 34642211 Free PMC article. Review.
The SWI/SNF chromatin remodeling complex, via nucleosome topology modulation, regulates transcription. The SMARCA4 (BRG1) subunit codes for the ATPase energy engine of the SWI/SNF complex. SMARCA4 is a tumor suppressor that is aberrant in 5% to 7% of human malignanc …
The SWI/SNF chromatin remodeling complex, via nucleosome topology modulation, regulates transcription. The SMARCA4 (BRG1) subunit cod …
Recent updates in thoracic SMARCA4-deficient undifferentiated tumor.
Nambirajan A, Jain D. Nambirajan A, et al. Semin Diagn Pathol. 2021 Sep;38(5):83-89. doi: 10.1053/j.semdp.2021.06.001. Epub 2021 Jun 4. Semin Diagn Pathol. 2021. PMID: 34147303 Review.
Among thoracic tumors, these include subsets of smoking-related non-small cell lung carcinoma (NSCLC) and a relatively rare, newly recognised tumor entity: thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT). Less than 100 cases of SMARCA4-UT have …
Among thoracic tumors, these include subsets of smoking-related non-small cell lung carcinoma (NSCLC) and a relatively rare, newly recognise …
Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer.
Liang X, Gao X, Wang F, Li S, Zhou Y, Guo P, Meng Y, Lu T. Liang X, et al. Cancer Med. 2023 Jul;12(13):14171-14182. doi: 10.1002/cam4.6083. Epub 2023 May 15. Cancer Med. 2023. PMID: 37184108 Free PMC article.
SMARCA4-dNSCLC patients have a worse prognosis than SMARCA4-iNSCLC patients (HR: 0.27; 95% CI: 0.17-0.45). ...CONCLUSION: SMARCA4-dNSCLC has unique clinicopathological features and a shorter survival prognosis than SMARCA4-iNSCLC. ...
SMARCA4-dNSCLC patients have a worse prognosis than SMARCA4-iNSCLC patients (HR: 0.27; 95% CI: 0.17-0.45). ...CONCLUSION: S …
A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers.
Peng L, Li J, Wu J, Xu B, Wang Z, Giamas G, Stebbing J, Yu Z. Peng L, et al. Front Immunol. 2021 Oct 4;12:762598. doi: 10.3389/fimmu.2021.762598. eCollection 2021. Front Immunol. 2021. PMID: 34675941 Free PMC article.
TMB, MSI, MMR, and DNA methylation correlated with SMARCA4 dysregulation in cancers. SMARCA4 expression was negatively associated with CD8+ T-cell infiltration in several tumors. ...SMARCA4 may correlate with tumor immunity....
TMB, MSI, MMR, and DNA methylation correlated with SMARCA4 dysregulation in cancers. SMARCA4 expression was negatively associa …
Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.
Longo V, Catino A, Montrone M, Montagna ES, Pesola F, Marech I, Pizzutilo P, Nardone A, Perrone A, Gesualdo M, Galetta D. Longo V, et al. Int J Mol Sci. 2024 Mar 13;25(6):3237. doi: 10.3390/ijms25063237. Int J Mol Sci. 2024. PMID: 38542211 Free PMC article. Review.
Recently, the fifth edition of the WHO classification recognized the thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) as a separate entity from conventional non-small cell lung cancer with SMARCA4 deficiency because of the different clinicopatho …
Recently, the fifth edition of the WHO classification recognized the thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4 …
SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature.
Nambirajan A, Singh V, Bhardwaj N, Mittal S, Kumar S, Jain D. Nambirajan A, et al. Arch Pathol Lab Med. 2021 Jan 1;145(1):90-98. doi: 10.5858/arpa.2019-0633-OA. Arch Pathol Lab Med. 2021. PMID: 33367658 Free article. Review.
CONTEXT.-: Somatic mutations in SMARCA4 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4) gene and/or BRG1 (Brahma-related gene 1) loss identifies a subset of non-small cell lung carcinomas (NSCLCs) lacking alterations in E …
CONTEXT.-: Somatic mutations in SMARCA4 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, mem …
SMARCA4-associated schwannomatosis.
Chan-Pak-Choon F, Roca C, Chong AS, Nogué C, Dahlum S, Austin R, Mar Fan H, van Spaendonck-Zwarts KY, Lambie NK, Robertson T, Siebert R, Rivera B, Foulkes WD. Chan-Pak-Choon F, et al. Acta Neuropathol. 2023 Apr;145(4):505-507. doi: 10.1007/s00401-023-02546-4. Epub 2023 Feb 14. Acta Neuropathol. 2023. PMID: 36786840 No abstract available.
SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions.
Deng Q, Lakra P, Gou P, Yang H, Meydan C, Teater M, Chin C, Zhang W, Dinh T, Hussein U, Li X, Rojas E, Liu W, Reville PK, Kizhakeyil A, Barisic D, Parsons S, Wilson A, Henderson J, Scull B, Gurumurthy C, Vega F, Chadburn A, Cuglievan B, El-Mallawany NK, Allen C, Mason C, Melnick A, Green MR. Deng Q, et al. Cancer Cell. 2024 Apr 8;42(4):605-622.e11. doi: 10.1016/j.ccell.2024.02.011. Epub 2024 Mar 7. Cancer Cell. 2024. PMID: 38458188 Free PMC article.
SMARCA4 is among the most recurrently mutated genes in human cancer, including 30% of germinal center (GC)-derived Burkitt lymphomas. In mice, GC-specific Smarca4 haploinsufficiency cooperated with MYC over-expression to drive lymphomagenesis. ...
SMARCA4 is among the most recurrently mutated genes in human cancer, including 30% of germinal center (GC)-derived Burkitt lymphomas. …
[SMARCA4-deficient thoracic tumors: A new entity].
Decroix E, Leroy K, Wislez M, Fournel L, Alifano M, Damotte D, Mansuet-Lupo A. Decroix E, et al. Bull Cancer. 2020 Jan;107(1):41-47. doi: 10.1016/j.bulcan.2019.12.001. Epub 2020 Jan 6. Bull Cancer. 2020. PMID: 31916995 Review. French.
Notably, they define 2 types of thoracic tumors: SMARCA4-deficient non-small cell lung carcinoma and SMARCA4-deficient sarcoma. Some clinical features appear to be common to both, such as intrathoracic localization, smoking exposure, male predominance and poor progn …
Notably, they define 2 types of thoracic tumors: SMARCA4-deficient non-small cell lung carcinoma and SMARCA4-deficient sarcoma …
2,159 results